Proveris Scientific to present a poster on factors effecting multi-dose nasal spray characteristics at RDD 2018

Proveris’s Senior Applications Chemist, Heli Chauhan, will be presenting a poster (Poster #25) titled “Impact of Actuator Design on Multi Dose Nasal Spray Characteristics.” The Respiratory Drug Delivery Conference will be held from April 22nd through the 26th, 2018 at the JW Marriott Starr Pass Resort & Spa Tucson, Arizona. Please see our conference announcement to learn more about our involvement as a Silver Sponsor or contact us at sales@proveris.com to request a private meeting with us while attending RDD!

Proveris will also host an Exhibition Table (#74). We encourage attendees to stop by to learn about our lab services and high performance OINDP testing instruments, including our new Kinaero™ High-Throughput Fire Down System.

Proveris Scientific Announces Participation in the 2018 RDD Conference

Marlborough, MA, March 27, 2018 – Proveris Scientific Corporation announces its participation in RDD (Respiratory Drug Delivery), a leading conference focusing on the development and commercialization of pulmonary and nasal pharmaceutical products. This five-day event will be held 22-26 April, 2018 at JW Marriott Starr Pass Resort & Spa Tucson, Arizona.

Attendees at the conference can learn how Proveris’s OINDP testing instruments, technologies and laboratory services can help gain understanding of product performance and the interactions between devices, formulations and human usage.

In addition to being a Silver Sponsor, Proveris will have a team of experts at their stand in the Technology Exhibition area and will present research on the Impact of Actuator Design on Multi Dose Nasal Spray Characteristics in the Scientific Poster Session. Visitors to the Proveris stand will be able to see the new Kinaero™ High-Throughput Fire Down System and learn how it increases pMDI testing efficiency in Product Development and QC workflows.

The Proveris team attending the conference are Ben Okorodudu, Vice President of Sales, Christopher Mapel, Sales Director for the Americas, Heli Chauhan, Senior Applications Chemist, and Denis Bonaccolta, Product Manager. “Our Silver Sponsorship and participation at RDD underscores our dedication to the advancement of high-quality science in the global inhalation community” said Ben Okorodudu. “We are looking forward to meeting with our customers to introduce our new products, and discuss how our technologies can help reduce product development timelines, and enhance product quality.”

About Proveris Scientific:

Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development the top spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.

Proveris announces spin-off of inhaler-specific voice guidance technology

Marlborough, MA, February 27, 2018 – Proveris Scientific announced today the spin-off of real-time, inhaler-specific voice guidance technology to Uneva Health, Inc. The technology is the core of a device/digital health platform Uneva Health is developing to reduce the enormous annual costs of inconsistent dosing caused by improper inhaler use while improving patient engagement and compliance. The platform includes a proprietary device that talks patients through inhaler use steps that are typically missed or done incorrectly, and mobile/web applications for viewing usage data.

“The platform will improve the safety and efficacy of marketed inhalers, and help ensure consistent dose delivery to millions of people suffering from asthma and COPD,” said Sue Farina, Uneva Health’s CEO and former Proveris President. “The opportunity to make a meaningful difference to help improve compliance and patient outcomes, while reducing healthcare costs is tremendous. Physicians and patients are anxiously waiting for the platform to be cleared for the market and see it as particularly helpful for pediatric and geriatric patient populations,” continued Farina.

The technology leverages Proveris Scientific’s decades of experience helping pharmaceutical companies bring effective orally inhaled and nasal drug products to market faster. “We’re excited about the technology’s potential and the fact that Proveris played a role in its creation,” said Chip Leveille, Proveris President. “Uneva Health is focused on the critical factors that affect patient use and we believe it will be very successful.”

Having completed a form factor, functioning hardware prototype, Uneva Health is currently raising seed funding for design-controlled development of its platform and is cultivating relationships for co-marketing opportunities with inhaled drug manufacturers.

About Uneva Health, Inc.


Uneva Health is a device/digital health platform company helping to improve the safety and efficacy of inhaled drug products, increase patient engagement and compliance, and reduce the costs of inconsistent dosing caused by improper drug product use and low patient confidence. The Uneva Health voice guidance platform helps patients when they need it most – when using their inhaled drug products. Headquartered in Massachusetts, the company is leveraging technology created from decades of experience related to the development and delivery of orally inhaled and nasal drug products, and hours of feedback from physicians, clinicians, insurers, and patients. For more information, please visit www.unevahealth.com or contact us at info@unevahealth.com.

About Proveris Scientific:

Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development the top spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’ systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.

Proveris Appoints Chip Leveille as President to Strengthen Operations, Transform for the Future

Marlborough, MA, February 1, 2018 – Proveris Scientific Corporation today announced Chip Leveille has been named President, effective immediately. As President, Leveille will have responsibility for all areas of corporate operations including Sales, Marketing, Business Development, Support, Product Development, Quality, Operations, Finance and Human Resources. He will report directly to Chief Executive Officer Dino Farina.

Proveris Scientific is a leading provider of services and technology to advance the science of nasal and inhaled drug delivery. “We are proud to name Chip Leveille as President of Proveris Scientific as we are entering an exciting phase,” said Dino Farina, Founder and CEO. “With his extensive commercial experience, Chip will drive the company in accelerated product, application and technology development. Key initiatives include improving how spray and aerosol drug delivery products are brought to market globally, and evaluating opportunities for expansion into new industries.”

Leveille brings extensive experience and insight into sales, marketing, product research and development, operations, corporate development, and regulatory affairs, based on his past senior leadership positions which includes a successful executive consulting business, senior executive and commercial leadership positions in biopharmaceutical technology providers including Affymetrix, BioScale, Helicos, and Zymark Corporation.

“I am very excited to lead Proveris in our next stage of growth,” says Leveille, “Proveris has very strong customer relationships, proven technologies and an untapped potential to provide new and innovative products that will help our customers bring the best performing spray and aerosol products to the global market.”

About Proveris Scientific:


Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development the top spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.

Proveris Scientific Joins IPAC-RS as an Associate Member

Marlborough, MA, April 24, 2017 – Proveris Scientific Corporation, a leading organization engaged in advancing the science of nasal and inhaled drug delivery, has joined The International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an associate member.

IPAC-RS is a highly respected technical resource and industry advocate for enhancing product quality for the benefit of patients who use orally inhaled and nasal drug products (OINDPs) to treat asthma, COPD and other respiratory diseases.
As an IPAC-RS Associate Member, Proveris and related member experts will collaborate in technical feasibility groups, knowledge networks and working groups related to the regulatory science of OINDPs. Proveris will participate in a wide range of IPAC-RS working groups from technology advancements to global regulatory review and outreach to emerging areas in India and China.

“We are excited to join IPAC-RS and have our team of experts positively contribute to advancing the global regulatory science of OINDPs via IPAC-RS working groups, technical committees and presentations, and outreach to rapidly developing regions such as India and China,” says Dino Farina, CEO of Proveris Scientific. “We hope to bring to the IPAC-RS community our 20+ years of collective experience working closely with generic and branded pharmaceutical companies, device suppliers, and global regulatory agencies that have provided us a unique perspective on some of the critical challenges that face our industry and how to bridge the knowledge gaps between patient use, formulation, device and regulatory compliance.
“IPAC-RS welcomes Proveris as an Associate Member. From our earliest days as a consortium, we have appreciated the perspectives and engagement of our supplier members and we look forward to Proveris’ involvement.” says Robert Berger, IPAC-RS Chair.

About IPAC RS


IPAC-RS is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDP) by collecting and analyzing data, and conducting joint research and development projects. Their members include innovator and generic companies that develop, manufacture or market orally inhaled and nasal drug products for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes. The association aims to build consensus and contribute to effective regulations and standards by sharing the results of our research through conferences, technical journals, and discussions with regulatory bodies. www.ipacrs.org

About Proveris Scientific Corporation

Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development of 5 of the top 7 spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.more information, please visit www.proveris.com.

Proveris SprayVIEW® Measurement System used in Development of First Generic Unit Dose Nasal Spray Approved by FDA

Marlborough, MA, April 19, 2016 – Proveris Scientific Corporation announced today that the Company’s SprayVIEW® measurement system was used by Summit Biosciences during development of the first generic unit dose nasal spray product approved by the FDA.

Approval of the abbreviated new drug application (ANDA) for Sumatriptan nasal spray USP, 5 mg and 20 mg was received by Lannett Company, Inc. from the U.S. Food and Drug Administration (FDA). Summit Biosciences developed the product and will manufacture commercial supplies for distribution by Lannett.
SprayVIEW® measurement systems are the gold standard for measuring spray pattern and plume geometry performance of orally inhaled and nasal drug products (OINDPs). The systems have been validated and are in use in development and production environments at generic and branded pharmaceutical companies, CDO/CMO/CROs, device manufacturers, and regulatory agencies around the world.

“Use of the Proveris SprayVIEW® measurement system was essential in helping us gain FDA approval,” said Greg Plucinski, COO of Summit Biosciences Inc. Dino Farina, CEO of Proveris Scientific said, “We are proud to work with Summit Biosciences as an essential component in their development of the world’s first generic unit-dose nasal spray drug product. We are committed to helping our customers rapidly bring successful drugs to market through sound science and innovative technologies.”

About Summit Biosciences

Summit Biosciences Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative nasal spray drug products. Summit’s headquarters and manufacturing facility is located on the University of Kentucky’s (UK) Coldstream Research Campus in Lexington, KY. In addition to developing an internal pipeline of products, the company provides a broad spectrum of services and expertise in nasal spray product development, manufacturing and analytical testing to pharmaceutical organizations with the goal of commercializing products for both the generic and branded Markets. Along with several generic products, the internal pipeline includes a delta-9 tetrahydrocannabinol (THC or medical marijuana) and products to treat pain. Since inception in late 2009, the company has created over 30 high-tech jobs in the Commonwealth of KY. With this approval and the anticipated commercialization of other Client sponsored and partnered products, Summit anticipates creating many additional high-tech jobs in the next few years.

About Proveris Scientific Corporation

Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development of 5 of the top 7 spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.

Proveris Scientific to present a poster on pMDIs at DDL26

Proveris’ CEO, Dino Farina, will be presenting a poster (Poster #65) titled “Understanding the importance and effects of shaking on pMDI performance“. The Drug Delivery to the Lungs Conference will be held from December 9th through the 11th, 2015 at the Edinburgh International Conference Centre, Edinburgh, Scotland, UK. Please visit our DDL26 page to learn more about our involvement as a Gold Sponsor and to request a private appointment with us while attending DDL!